Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source
No articles found.
T2 Biosystems, a leader in the development and commercialization of innovative med...
T2 Biosystems, a leader in the development and ...
Moderna is advancing messenger RNA (mRNA) science to create a new class of transfo...
Moderna is advancing messenger RNA (mRNA) scien...
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Cerecor is an integrated biopharmaceutical company developing innovative therapies...
Cerecor is an integrated biopharmaceutical comp...
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing an...
Soligenix, Inc. is a late-stage biopharmaceutic...
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treat...
Ardelyx is focused on enhancing the way people ...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
We are a clinical-stage biopharmaceutical company focused on developing and provid...
We are a clinical-stage biopharmaceutical compa...
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...
Mirum Pharmaceuticals Inc. is a clinical-stage ...
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the...
Ritter Pharmaceuticals, Inc. develops novel the...
Join the National Investor Network and get the latest information with your interests in mind.